このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Transauricular Vagus Nerve Stimulation Frequencies for Postoperative Pain (TVNS-PAIN)

2026年6月7日 更新者：Joao Paulo Aureliano de Carvalho、Federal University of Bahia

Effects of Different Frequencies of Transauricular Vagus Nerve Stimulation on Postoperative Pain: A Randomized, Double-Blind, Sham-Controlled Trial With Preoperative and Postoperative Sessions

The goal of this clinical trial is to learn whether different frequencies of transauricular vagus nerve stimulation (tVNS) can reduce postoperative pain and opioid consumption in adults undergoing abdominal or urologic surgery. It will also evaluate the effects of tVNS on recovery quality, autonomic function, and treatment safety. The main questions it aims to answer are:

Does transauricular vagus nerve stimulation reduce postoperative opioid consumption during the first 24 hours after surgery? Do different stimulation frequencies (high-frequency and low-frequency tVNS) produce different effects on postoperative pain and autonomic responses? Is transauricular vagus nerve stimulation safe and well tolerated in surgical patients?

Researchers will compare high-frequency tVNS, low-frequency tVNS, and sham stimulation (inactive stimulation) to determine their effects on postoperative pain and opioid requirements.

Participants will:

Be randomly assigned to receive high-frequency tVNS, low-frequency tVNS, or sham stimulation.

Receive two 30-minute stimulation sessions, one before anesthesia and one after surgery in the post-anesthesia care unit.

Undergo assessments of postoperative pain, opioid consumption, need for rescue analgesics, postoperative nausea and vomiting, heart rate changes, and quality of recovery.

Be monitored for adverse events related to the intervention during the study period.

A total of 174 participants will be enrolled in this single-center, randomized, double-blind, sham-controlled clinical trial.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Postoperative pain remains a major challenge in perioperative care and is associated with delayed recovery, increased healthcare utilization, and greater opioid consumption. Despite advances in multimodal analgesia, opioid medications continue to play a central role in postoperative pain management and may be associated with adverse effects such as nausea, vomiting, respiratory depression, and prolonged recovery. Therefore, the development of effective non-pharmacological adjunctive strategies is of considerable clinical interest.

Transauricular vagus nerve stimulation (tVNS) is a non-invasive neuromodulation technique that stimulates the auricular branch of the vagus nerve through the external ear. Experimental and clinical studies suggest that vagal stimulation may modulate pain perception through activation of central autonomic pathways, enhancement of descending inhibitory pain mechanisms, and regulation of inflammatory responses. Previous clinical trials have demonstrated promising effects of tVNS on acute and chronic pain conditions, including reductions in postoperative pain scores.

However, the optimal stimulation parameters for perioperative analgesia remain uncertain. In particular, the influence of stimulation frequency on clinical outcomes and autonomic responses has not been adequately investigated. Different stimulation frequencies may activate distinct neural pathways and produce different effects on pain modulation and autonomic regulation.

This study is designed to evaluate the effects of different frequencies of transauricular vagus nerve stimulation applied before and after surgery in adult patients undergoing elective surgical procedures. In addition to assessing postoperative opioid requirements, the study will explore the relationship between autonomic responses and postoperative recovery. The findings may contribute to the optimization of non-pharmacological analgesic strategies and support the incorporation of transauricular vagus nerve stimulation into multimodal perioperative pain management protocols.

研究の種類

介入

入学 (推定)

174

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前：Rodrigo L Alves, MD, PhD
  • 電話番号：71 99961-9818
  • メール：rlalves@ufba.br

研究連絡先のバックアップ

研究場所

  • ブラジル
    • Estado de Bahia
      • Salvador、Estado de Bahia、ブラジル、40170-110
        • 募集
        • Hospital Universitário Professor Edgard Santos, Federal University of Bahia (HUPES-UFBA)
        • コンタクト：

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Adults aged 18 to 59 years.
  • Undergoing elective abdominal or urologic surgery.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • History of neurological disorders.
  • History of psychiatric disorders.
  • Inability to understand study procedures.
  • Pregnancy.
  • Cognitive impairment.
  • Communication difficulties that interfere with study assessments.
  • Auricular dermatitis or skin lesions at the stimulation site.
  • Pre-existing cardiac arrhythmia.
  • Chronic opioid use.
  • Implanted electronic medical devices, including pacemakers.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的：High-Frequency tVNS
Participants will receive active transauricular vagus nerve stimulation (tVNS) at a frequency of 60-120 Hz. Stimulation will be applied bilaterally to the auricular branch of the vagus nerve for 30 minutes before anesthesia and for 30 minutes after surgery. Current intensity will be adjusted between 2 and 6 mA according to participant tolerance.
デバイス：Transauricular Vagus Nerve Stimulation (tVNS)
Non-invasive electrical stimulation of the auricular branch of the vagus nerve applied bilaterally through ear electrodes. Stimulation is delivered before anesthesia and after surgery using predefined frequency settings.
実験的：Low-Frequency tVNS
Participants will receive active transauricular vagus nerve stimulation (tVNS) at a frequency of 10-20 Hz. Stimulation will be applied bilaterally to the auricular branch of the vagus nerve for 30 minutes before anesthesia and for 30 minutes after surgery. Current intensity will be adjusted between 2 and 6 mA according to participant tolerance.
デバイス：Transauricular Vagus Nerve Stimulation (tVNS)
Non-invasive electrical stimulation of the auricular branch of the vagus nerve applied bilaterally through ear electrodes. Stimulation is delivered before anesthesia and after surgery using predefined frequency settings.
偽コンパレータ：Sham tVNS
Participants will receive sham transauricular vagus nerve stimulation. The device will be positioned and activated to mimic active treatment, but stimulation will be discontinued shortly after initiation. Participants will undergo two 30-minute sessions, one before anesthesia and one after surgery, while maintaining blinding to treatment allocation.
デバイス：Sham Transauricular Vagus Nerve Stimulation (sham tVNS)
Sham stimulation delivered using the same device and electrode placement as active stimulation. The device is activated to mimic treatment but does not deliver therapeutic electrical stimulation.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Total postoperative opioid consumption during the first 24 hours after surgery
時間枠：24 hours after surgery
Total opioid consumption during the first 24 postoperative hours, recorded according to the institutional postoperative analgesia protocol.
24 hours after surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Postoperative pain intensity (VAS)
時間枠：Before stimulation in the post-anesthesia care unit, immediately after stimulation, 2 hours after surgery, and 24 hours after surgery
Pain intensity measured using a 100-mm Visual Analog Scale (VAS). Pain scores will be assessed at predefined postoperative time points and compared among study groups.
Before stimulation in the post-anesthesia care unit, immediately after stimulation, 2 hours after surgery, and 24 hours after surgery
Rescue analgesic use
時間枠：Within 24 hours after surgery
Number of participants requiring rescue analgesics and total rescue analgesic administration during the first 24 postoperative hours.
Within 24 hours after surgery
Postoperative nausea and vomiting (PONV)
時間枠：Within 24 hours after surgery
Incidence of postoperative nausea and/or vomiting and use of rescue antiemetic medication during the postoperative period.
Within 24 hours after surgery
Heart rate changes
時間枠：Immediately before and immediately after each stimulation session (preoperative and postoperative).
Changes in heart rate measured immediately before and immediately after transauricular vagus nerve stimulation sessions as an indicator of autonomic nervous system activity.
Immediately before and immediately after each stimulation session (preoperative and postoperative).
Quality of Recovery (QoR-15 Score)
時間枠：Baseline (preoperative) and 24 hours after surgery.
Quality of postoperative recovery assessed using the 15-item Quality of Recovery questionnaire (QoR-15). Higher scores indicate better recovery.
Baseline (preoperative) and 24 hours after surgery.
Adverse events related to transauricular Vagus Nerve Stimulation
時間枠：From the first stimulation session until 24 hours after surgery.
Incidence of adverse events potentially related to the intervention, including auricular discomfort, skin irritation, headache, bradycardia, hypotension, bronchospasm, or other treatment-related events.
From the first stimulation session until 24 hours after surgery.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Federal University of Bahia

協力者

Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil

捜査官

  • 主任研究者：Rodrigo M Vieira, MD、Botucatu Medical School, São Paulo State University (UNESP)

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2026年11月30日

研究の完了 (推定)

2026年12月4日

試験登録日

最初に提出

2026年6月2日

QC基準を満たした最初の提出物

2026年6月2日

最初の投稿 (実際)

2026年6月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月10日

QC基準を満たした最後の更新が送信されました

2026年6月7日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 96691226.0.0000.0049 (レジストリ識別子：8.416.413)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data underlying the results reported in publications arising from this study will be made available, including demographic characteristics, intervention allocation, primary and secondary outcome measures, and adverse event data. Data will be shared only after removal of all direct identifiers to protect participant confidentiality.

IPD 共有時間枠

De-identified individual participant data and supporting study documents will be available beginning 3 months after publication of the primary study results and will remain available indefinitely, with no end date.

IPD 共有アクセス基準

De-identified data will be available to qualified researchers who provide a methodologically sound research proposal. Requests should be submitted to the principal investigator. Access will be granted following review and approval of the proposed use and execution of a data-sharing agreement.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する